FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114902110> ?p ?o ?g. }

• W2114902110 endingPage "3594" @default.
• W2114902110 startingPage "3588" @default.
• W2114902110 abstract "Chronic kidney disease (CKD) patients affected by mineral bone disorders (MBD) have higher rates of all-cause and cardiovascular-related mortality. Approximately, one-third of dialysis patients have low serum parathyroid hormone (PTH) levels (≤150 pg/mL). However, the reason why these patients have higher mortality compared to patients with normal PTH levels has not yet been fully elucidated. The FARO study was performed on 2453 Italian patients followed prospectively from 28 dialysis centres over a 2-year period. Data were collected every 6 months and end points included time-to-death cumulative probability in patients with serum intact PTH (iPTH) ≤150 pg/mL and the effect of vitamin D receptor activation (VDRA) therapy. Kaplan–Meier curves and proportional hazards regression models stratified by PTH levels (i.e. ≤150 and >150 pg/mL) were used to determine cumulative probability of time-to-death and adjusted hazard ratios (HRs) for demographic, clinical and CKD-MBD treatment characteristics. The cumulative probability of death was higher (P < 0.01) for patients with serum iPTH levels ≤150 pg/mL [25.1%, 95% confidence interval (CI): 22.1–28.5 at 18 months] versus those with serum iPTH levels within the normal range (18.0%, 95% CI: 16.1–20.1). In a model with time-dependent covariates restricted to time periods when patients had iPTH levels ≤150 pg/mL, lower mortality was observed in patients treated with VDRA [i.e. HR = 0.62, 95% CI: 0.42–0.92 for oral or intravenous (IV) calcitriol; HR = 0.18, 95% CI: 0.04–0.8 for IV paricalcitol] versus those not receiving any VDRA (P < 0.01) independently of other variables. Patients who received IV paricalcitol, compared with either oral or IV calcitriol, showed reduced mortality, but this was not statistically significant (HR = 0.3, 95% CI: 0.07–1.31, P = 0.11). Results from this observational study suggest that VDRA therapy was associated with improved survival in dialysis patients, even with low serum iPTH levels." @default.
• W2114902110 created "2016-06-24" @default.
• W2114902110 creator A5000710758 @default.
• W2114902110 creator A5001391327 @default.
• W2114902110 creator A5008053180 @default.
• W2114902110 creator A5018320268 @default.
• W2114902110 creator A5024121378 @default.
• W2114902110 creator A5045507293 @default.
• W2114902110 creator A5048493904 @default.
• W2114902110 creator A5064594935 @default.
• W2114902110 creator A5072724625 @default.
• W2114902110 creator A5074905047 @default.
• W2114902110 creator A5079688648 @default.
• W2114902110 creator A5086015233 @default.
• W2114902110 date "2012-04-20" @default.
• W2114902110 modified "2023-09-25" @default.
• W2114902110 title "VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH <=150 pg/mL: results of the Italian FARO Survey" @default.
• W2114902110 cites W1949626690 @default.
• W2114902110 cites W1988779242 @default.
• W2114902110 cites W1996856345 @default.
• W2114902110 cites W2006390192 @default.
• W2114902110 cites W2009949027 @default.
• W2114902110 cites W2014348675 @default.
• W2114902110 cites W2021514219 @default.
• W2114902110 cites W2028127512 @default.
• W2114902110 cites W2031941775 @default.
• W2114902110 cites W2035221187 @default.
• W2114902110 cites W2053623915 @default.
• W2114902110 cites W2055220862 @default.
• W2114902110 cites W2069112436 @default.
• W2114902110 cites W2074826032 @default.
• W2114902110 cites W2080387599 @default.
• W2114902110 cites W2083921658 @default.
• W2114902110 cites W2105417592 @default.
• W2114902110 cites W2113356410 @default.
• W2114902110 cites W2113593985 @default.
• W2114902110 cites W2122037712 @default.
• W2114902110 cites W2127561755 @default.
• W2114902110 cites W2128372431 @default.
• W2114902110 cites W2133134475 @default.
• W2114902110 cites W2136670164 @default.
• W2114902110 cites W2136722090 @default.
• W2114902110 cites W2137743950 @default.
• W2114902110 cites W2138829372 @default.
• W2114902110 cites W2139277511 @default.
• W2114902110 cites W2142591987 @default.
• W2114902110 cites W2157325579 @default.
• W2114902110 cites W2166775378 @default.
• W2114902110 cites W2327200633 @default.
• W2114902110 cites W4211046201 @default.
• W2114902110 cites W4250592055 @default.
• W2114902110 cites W77247516 @default.
• W2114902110 doi "https://doi.org/10.1093/ndt/gfs108" @default.
• W2114902110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22523119" @default.
• W2114902110 hasPublicationYear "2012" @default.
• W2114902110 type Work @default.
• W2114902110 sameAs 2114902110 @default.
• W2114902110 citedByCount "52" @default.
• W2114902110 countsByYear W21149021102012 @default.
• W2114902110 countsByYear W21149021102013 @default.
• W2114902110 countsByYear W21149021102014 @default.
• W2114902110 countsByYear W21149021102015 @default.
• W2114902110 countsByYear W21149021102016 @default.
• W2114902110 countsByYear W21149021102017 @default.
• W2114902110 countsByYear W21149021102018 @default.
• W2114902110 countsByYear W21149021102019 @default.
• W2114902110 countsByYear W21149021102020 @default.
• W2114902110 countsByYear W21149021102022 @default.
• W2114902110 countsByYear W21149021102023 @default.
• W2114902110 crossrefType "journal-article" @default.
• W2114902110 hasAuthorship W2114902110A5000710758 @default.
• W2114902110 hasAuthorship W2114902110A5001391327 @default.
• W2114902110 hasAuthorship W2114902110A5008053180 @default.
• W2114902110 hasAuthorship W2114902110A5018320268 @default.
• W2114902110 hasAuthorship W2114902110A5024121378 @default.
• W2114902110 hasAuthorship W2114902110A5045507293 @default.
• W2114902110 hasAuthorship W2114902110A5048493904 @default.
• W2114902110 hasAuthorship W2114902110A5064594935 @default.
• W2114902110 hasAuthorship W2114902110A5072724625 @default.
• W2114902110 hasAuthorship W2114902110A5074905047 @default.
• W2114902110 hasAuthorship W2114902110A5079688648 @default.
• W2114902110 hasAuthorship W2114902110A5086015233 @default.
• W2114902110 hasBestOaLocation W21149021101 @default.
• W2114902110 hasConcept C124490489 @default.
• W2114902110 hasConcept C126322002 @default.
• W2114902110 hasConcept C126894567 @default.
• W2114902110 hasConcept C134018914 @default.
• W2114902110 hasConcept C151032500 @default.
• W2114902110 hasConcept C207103383 @default.
• W2114902110 hasConcept C2776079296 @default.
• W2114902110 hasConcept C2778063415 @default.
• W2114902110 hasConcept C2778653478 @default.
• W2114902110 hasConcept C2779978075 @default.
• W2114902110 hasConcept C2781208988 @default.
• W2114902110 hasConcept C44249647 @default.
• W2114902110 hasConcept C50382708 @default.
• W2114902110 hasConcept C519063684 @default.
• W2114902110 hasConcept C71924100 @default.

• next